NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Yellowstone Biosciences

Yellowstone Biosciences

Private
OxfordHealthcare & Life Scienceshttps://yellowstonebio.com/

Last Round

Series A

Jun 20, 2024

Total Funding Raised

$21M

Company Overview

Yellowstone Biosciences is a biotechnology company that develops soluble bispecific T-cell receptor-based therapies targeting HLA Class II antigens for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

bispecific T-cell receptorTCR therapeuticsacute myeloid leukemiaAMLHLA Class IIcancer immunotherapyoncology drug discoverybiotech drug pipelineprotein engineeringtargeted cancer therapysolid tumor treatmentbiologics R&Dnext-gen immunotherapydrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Yellowstone Biosciences Comparables

Compare Yellowstone Biosciences with similar companies based on industry and business-model similarity.

Yellowstone Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stereo Biotherapeutics
80%
Enara Bio
78%
T-knife Therapeutics
78%

Yellowstone Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 20, 2024

Key People

Founding team and executive leadership

Julian Hirst

Co-Founder & Chief Financial Officer

Founding Team

Ita O'Kelly

Chief Operating Officer

Executive Team

Yellowstone Biosciences Investors

Notable investors and investment history

Yellowstone Biosciences investors
InvestorRounds
SynconaSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 8, 2025

    Grew 18% QoQ, from 22 to 26 employees.

  • May 4, 2025

    Grew 19% QoQ, from 21 to 25 employees.

Yellowstone Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Yellowstone Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Yellowstone Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range29
Year Founded2023
Last FundingJun 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.